Drugs / CT-044
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04252833 | Feb → Mar 2020 | peripheral neuropathy | Lotus Clinical Research, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04175743 | Dec 2019 → Aug 2020 | — | Lotus Clinical Research, LLC | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04175743 ↗ |
| Known as | CT-044 HCl | “CT-044 HCl is a reactive species decomposition accelerant” NCT04175743 ↗1“CT-044 HCl is a reactive species decomposition accelerant” NCT04252833 ↗ |
| Route | Oral | “Subjects will receive multiple oral CT-044 HCl doses for 7 days.” NCT04175743 ↗ |